Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program

Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program

Shots:

  • Iconic to receive $7.5M upfront, funds for preclinical development and is eligible for option exercise payment, development, regulatory & commercial milestones, royalties on sales. Exelixis to get an option to license Iconic’s ICON-2 ADC program and will exercise its option at IND filing
  • The focus of the collaboration is to robust Exelixis’s oncology portfolio by developing therapies utilizing Iconic’s Tissue Factor antibody expertise
  • ICON-2 is a second-generation ADC targeting Tissue Factor in solid tumors as TF overexpression accelerates angiogenesis, metastasis leading to tumor development and progression

Click here to read full press release/ article | Ref: Exelixis | Image: Iconic Therapeutics